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Abstract
Background: There are no validated measuring tools to gauge the effectiveness of a Hospital
Palliative Care Consultation Team (PCCT). One way would be to consider its effect on the
consumption of opioids expressed in total amounts and different formulations administered. We
perform this study to evaluate the impact of a hospital PCCT on the trends of opioid prescription
in a University Hospital.
Methods: A seven year retrospective study on opioid prescription was carried out in the Clínica
Universidad de Navarra. The period includes three years before and three years after the PCCT
was implemented. Prescription was analysed calculating yearly the Defined Daily Dose (DDD)
adjusted to 1000 hospital stays (DDD/1000HS). Indicators considered were the proportion of
patients treated using opioids compared to the total estimated in need of treatment (rate of
effectiveness) and the proportion of patients potentially requiring opioids but not treated who
were incorporated into the treatment group (rate of improvement).
Results: From 2001 to 2007, total opioid prescription was low in non-oncology Departments
(range: 69–110 DDD/1000HS) while parenteral morphine and fentanyl did not register any changes.
In the same period of time, total opioid prescription increased in the Oncology Department from
240 to 558 DDD/1000HS. The rate of effectiveness in the three years prior to the implantation of
the consultation team was 64% and in the three following years rose to 87%. The rate of
improvement prior to the palliative care consultation team was 43% and in the three following
years was 64%. A change in opioid prescription was registered after the implementation of the
PCCT resulting in an increase in the prescription of parenteral morphine and methadone and a
decrease in transdermal fentanyl.
Conclusion: Implementation of a PCCT in a University Hospital is associated with a higher and
more adequate use of opioids.
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Pain relief is one of the key issues for advanced-stage can-
cer patients and their carers. The World Health Organiza-
tion (WHO) analgesic ladder recommended the use of
weak and strong opioid to treat pain [1]. Data from the
early 1990s described that 40% cancer patients do not
receive sufficient pain relief [2,3]. However, in the last
years there has been a steady increase in the prescription
of opioids for the treatment of pain, especially in devel-
oped countries, including Spain [4].
There is evidence of the efficiency of interdisciplinary pal-
liative care teams, based in hospitals and cancer centres
[5]. A particular kind of these teams are the Palliative Care
Consultation Team (PCCT) appeared in the 1970s. A
PCCT, usually does not have patient beds under its
responsibility but rather it acts in an advisory role to other
healthcare professionals and works with the aim of bring-
ing palliative care principles into acute care hospitals [6-
8]. The aim of improving palliative care in all hospital
patients is achieved by providing direct care by the team
and by offering advice to attending doctors [9], as well as
by trying to influence the work of other care professionals
and staff members [10,11]. The goal is that patients in
need of palliative care admitted to any department will
receive appropriate care even without the direct interven-
tion of a specialised palliative care team [12,13].
It is estimated that in the USA, 50% of hospitals have a
palliative care team, or plan to set one up soon [14]. In
Europe, the countries with the most developed Consulta-
tion teams are the United Kingdom and France where over
300 services of this type have been identified, correspond-
ing to 35% and 65% of all palliative care units respectively
[15]. Data exists which suggest that patients cared for by
consultation teams have better assessment of problems
and achieve better symptom management [16-18]. Never-
theless, the evaluation of the impact of these consultation
teams has been generally limited only to those patients
treated directly by the team, without taking into account
the whole institution where their influence can be meas-
ured on a larger scale.
Pain is one of the most common symptoms occurring in
cancer and for many years, opioid prescription has been
used as an indicator of appropriate care [19]. In the same
way, the impact of the consultation team may be meas-
ured in the changes in opioid prescription within the set-
ting where they operate. It is reasonable to expect that
their work may result in an increase in the total amount of
opioids prescribed in the centre as a whole or at least in
those departments targeted by the consultation team. In
France, for example, part of the assessment of the hospital
consultation teams includes analysing the total amount of
opioids prescribed in the hospital where they operate.
In November 2004, a palliative PCCT started its work at
the Clínica Universidad de Navarra, a 300 bed teaching
hospital. Initially the team's activity was centred on cancer
patients. The PCCT is integrated in the Oncology Depart-
ment and consisted of two doctors, two nurses, a psychol-
ogist and a researcher; it provide support to the whole
Oncology Department, composed of 21 oncologists. The
PCCT dealt mainly with hospital inpatients, although
over time, an increasing number of outpatients were also
seen. During the course of its third year, it treated 20% of
the 1842 inpatients at the Oncology Department that
induced 10896 hospital stays.
There is no known level of opioid prescription which may
be considered the ideal for a teaching hospital. In any
case, a maximum can be estimated in function of the
number of inpatients with severe pain. It can also be
assumed that the consultation team has some influence
on the type of opioids consumed in the hospital, in that
the chosen medications and formulations will be
expected to be those considered most effective and safe to
meet the patients' needs.
This study was designed to measure the influence of a
PCCT expressed as the impact on the trends of opioid pre-
scription in a University Hospital. To do that, we analyse
the patterns in opioid prescription for patients admitted
to the Clínica Universidad de Navarra and design indica-
tors of efficiency and effectiveness in pain treatment in
cancer patients.
Methods
A study was performed analyzing the amount and type of
opioids prescribed to inpatients at the Oncology Depart-
ment and other Departments at the Clínica Universidad
de Navarra, between October 1st 2001 and September 30th
2007, covering the three years prior to and the three years
following the setting up of the consultation palliative care
team. Inpatients in departments different from Oncology
were assigned to a control group. Opioids included in the
study were those which can be administered at regular
intervals (oral and parenteral morphine, oral and
parenteral methadone, oxycodone and transdermal fenta-
nyl). Opioids excluded were transmucous oral fentanyl,
(use limited to breakthrough pain), intravenous fentanyl
and remifentanil (used limited to diagnostic tests) and
transdermal buprenorphine (not yet listed in the Hospi-
tal's Pharmacotherapy Guide).
The Pharmacy Department supplied the data on the quan-
tity and formulations of opioids prescribed and dispensed
to inpatients of the Oncology Department. Using this
data, the Defined Daily Dose (DDD) for each opioid and
for each administration route [20] was calculated. The
DDD represents the average daily maintenance dose of aPage 2 of 7
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and it is expressed as the amount of active ingredient in
milligrams, according to its therapeutic equivalence and
route of administration (Table 1) [21]. In the calculations
for the DDD of transdermal fentanyl consideration was
made only of the dose absorbed by the patient in three
days and not the dosage in each patch.
The total number of DDD was adjusted to the annual
length of stay in the Oncology Department in thousands.
The following formula was applied: DDD per 1000 hospi-
tal stays divided by the total annual length of stay per year
(DDD/1000HS = total DDD × 1000 × annual length of
stay-1) per year.
In order to obtain indicators of efficiency and improve-
ment in pain treatment an estimate on the number of
patients admitted with cancer pain was calculated using
the rationale that approximately 80% of patients with
advanced stages suffer pain [22,23]. Since the Oncology
Department already treats patients with diverse stages of
the illness, it is reasonable to expect that the percentage of
patients suffering from pain might be somewhere
between 50% and 80%. For the purpose of this study, the
higher figure was chosen. Of these cancer patients suffer-
ing pain that requires opioid treatment has been esti-
mated to be around 80% [24,25]. This means that
approximately 64% of all patients at the Oncology
Department should be ideally treated with opioids.
Following this estimate, as DDD represents the average
daily maintenance dose, as long as all those in need do
indeed receive opioid treatment the ideal DDD per thou-
sand cancer patients should move around 640. If we take
this reference as valid, the efficiency of pain treatment for
a cohort of cancer patients can be estimated by calculating
the proportion of patients receiving opioid treatment in
relation to the total calculated number in need. As a lineal
relation can be estimated between total DDD and the
number of patients receiving opioids, data of DDD pre-
scribed to Oncology patients are an indicator of pain treat-
ment efficiency. It is expressed in thousands of hospital
stays per year and shown in relation to the ideal maxi-
mum estimated annual use and can be established as
DDD/1000HS × 640-1 (and multiplied × 100 to present
the proportion as percentage).
Based on the estimated figure that 64% of cancer inpa-
tients require opioids, it is possible to calculate the per-
centage of patients who should be receiving this kind of
treatment and those who are not as well as estimate how
this difference changes every year. This indicator of
improvement in pain treatment is estimated as (Final
DDD/1000HS - Initial DDD/1000HS) × (640 - Initial
DDD/1000HS)-1 (and multiplied × 100 to present the
proportion as percentage).
Results
Table 2 shows the DDD/1000HS for each opioid dis-
pensed by the Pharmacy Department to the Oncology
Department during the 2001–2007 period. As the use of
meperidine in Oncology was minimal (14–43 units per
year), it was excluded from this analysis. During the three
years prior to initiation of the PCCT, the total prescription
of opioids rose sharply from 240 to 411 DDD/1000HS.
After three years it rose to 558 DDD-1000HS. Opioid con-
sumption between 2001 and 2007 in the other Depart-
ments was much lower than the one observed in
Oncology and demonstrated a steady trend (between 56
and 94 DDD/1000HS) (Table 3).
The indicators for efficiency and improvements are shown
on Table 4. At the beginning of the period, the consulta-
tion team prescribed opioids to 64% of the estimated
patients in need. At the end of the three year period, effi-
ciency had risen to 87%.
The rate of improvement measured as the percentage of
patients who began to receive opioids of those estimated
in need every year was 12%, 11% and 27% during the
three years prior to the consultation team. After the con-
sultation team started, the first year resulted in a negative
growth (-7%) although it rose sharply to 54% and 27%
the following two years. Overall, the rate of improvement
for the three years prior and the three years following the
start of the PCCT team was 43% and 64% respectively.
In regards to the trends in opioid prescription at the
Oncology Department (Figure 1), the three years prior to
beginning the work of the PCCT a steady increase in the
prescription of both transdermal fentanyl (from 101 to
222 DDD/1000HS) and parenteral morphine (from 70 to
120 DDD/1000HS) was observed, whilst prescription of
oral morphine and methadone did not change. Oxyco-
done had still not been released commercially.
After the beginning of the work of the consultation team
in 2004, the consumption of oral methadone rose almost
ten-fold (from 7 to 68 DDD/1000HS in 2007). In regards
Table 1: Equivalence in the Defined Daily Dose (DDD) for 
different opioids (see reference 20).
Opioid DDD (mg)
Parenteral morphine 30
Oral morphine 100
Parenteral methadone 25
Oral methadone 25
Oral oxycodone 75
Transdermal fentanyl 1.2Page 3 of 7
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scription continued to increase steadily until it shot up the
following year (from 120 to 289 DDD/1000HS). Never-
theless, a sharp fall was seen in the use of transdermal fen-
tanyl to levels in line with those of 2001 (from 222 to 103
DDD/1000HS) whilst the prescription of oral morphine
and parenteral methadone remained steady. Oxycodone
was released commercially in 2004 and its consumption
reached 29 DDD/1000HS in 2007. For the rest of the Hos-
pital, the most commonly used opioids were parenteral
morphine and transdermal fentanyl, with few changes
over the years.
Discussion
Expressing annual hospital opioid prescriptions in terms
of the number of DDD per thousand hospital stays is a
new way of presenting such data. Previous publications
have used other indicators of morphine equivalent doses
and generally do not standardise a particular number of
individuals [26]. The concept of DDD provides an indica-
tor of the proportion of patients receiving adequate pain
treatment and how each type of opioid is used. DDD, a
measurement designed for Cross-National Drug Utiliza-
tion Studies [20], allows for the comparison of results
internationally and between centres. In addition, the rate
of efficiency described in this study offers an initial esti-
mation of the quality of pain treatment among a group of
patients. At the outset of the work of the PCCT, two out of
every three patients needing opioids were receiving them.
After three years, the percentage had risen to 90%. In
regards to the improvement rate, in the three years prior
to setting up the consultation team 43% of patients esti-
mated in pain were initiated in opioid treatment, whilst in
the three following years this figure rose to 64%. This
seems to indicate that the speed at which opioid prescrip-
tion increased was greater after the PCCT began its work.
It is striking that the start of the PCCT's activity did not
result in an increase in the percentage of patients receiving
opioids. Nevertheless, that was the same year which saw
the most important change in the type of opioids pre-
scribed: the increasing trend in the use of fentanyl
declined but there was no coincident growth in the use of
prescribed morphine. This suggests the existence of a sub-
group of patients who are being over-treated with
transdermal fentanyl. This first effect was soon compen-
sated and the rate of growth for the following year was
clearly positive, as if trying to make up lost ground. Not-
withstanding, any assessment would require knowledge
of the natural behaviour or development of this indicator
free from the influence of a consultation team. Neither
should it be assumed that the observed changes in opioid
prescription are due only to the efficiency of the work of
the consultation team. Since they are Oncology inpa-
tients, it is logical to think that this is an indicator of an
improvement in the knowledge and skills on pain man-
agement by the oncologists, maintaining the previous
trend and also receiving the support of a new PCCT. It is
Table 2: Prescription of opioids in hospitalized patients in the Oncology Department in Daily Defines Doses per 1000 hospital stays 
(DDD/1000HS) per year.
Opioid 2001 2002 2003 2004 2005 2006 2007
Parenteral morphine 70 79 114 120 127 242 289
Oral morphine 52 43 48 56 55 70 65
Oxycodone 0 0 0 0 5 28 29
Parenteral methadone 8 4 5 6 3 0 4
Oral methadone 9 2 2 7 22 30 68
Transdermal fentanyl 101 160 157 222 184 158 103
Total DDD/1000HS 240 288 326 411 396 528 558
Table 3: Prescription of opioids in hospitalized patients in Departments others than Oncology in Daily Defined Doses per 1000 hospital 
stays (DDD/1000HS) per year.
Opioid 2001 2002 2003 2004 2005 2006 2007
Parenteral morphine 43 40 40 44 47 64 61
Oral morphine 3 1 2 2 2 3 2
Oxycodone 0 0 0 0 1 3 2
Parenteral methadone 4 1 1 0 0 1 0
Oral methadone 1 1 0 1 1 2 3
Transdermal fentanyl 18 13 19 24 26 37 26
Total DDD/1000HS 69 56 62 71 77 110 94Page 4 of 7
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changes in the type of opioid used and in the administra-
tion routes. The other departments in the hospital, used as
control groups in the study, presented a steadily low opi-
oid consumption. This led us to think that the changes in
Oncology were not due to institutional bias, nor to
changes in the policy of opioid consumption in the hos-
pital as a whole.
A change was noted in the trend in the use of opioid for-
mulations for Oncology inpatients. Parenteral morphine
registered higher utilization than transdermal fentanyl,
more than any other opioid and more than oral mor-
phine. Morphine is considered as more appropriate than
fentanyl for cancer patients in acute care centres as it
allows for quicker adjustments and better management in
the prevention of opioid toxicity. The higher utilization of
Table 4: Proposed Indicator of efficiency and ratio of improvement in pain treatment in oncology inpatients
Indicators 2001 2002 2003 2004 2005 2006 2007
Efficiency index 37% 45% 50% 64% 61% 82% 87%
Rate of improvement - 12% 11% 27% -7% 54% 27%
(we estimate that 64% of oncology inpatients have to be under opioid treatment: see in the text). Efficiency index [DDD/1000HS × 640-1 × 100]: 
Proportion of patients receiving opioid treatments in relation to the total number estimated who should be receiving them. Rate of improvement 
[(Final DDD/1000HS - Initial DDD/1000HS) × (640 - Initial DDD/1000HS)-1 × 100]: Proportion of patients requiring opioids who began to use them 
in the time considered.
Trends in prescription of the most relevant opioids in hospitalized patients in the Oncology Department, in Daily Defines Doses per 1000 hospital stays (DDD/1000HS) per year. Palli t v  Care Unit start at 2004.Figure 1
Trends in prescription of the most relevant opioids in hospitalized patients in the Oncology Department, in 
Daily Defines Doses per 1000 hospital stays (DDD/1000HS) per year. Palliative Care Unit start at 2004.Page 5 of 7
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phine must to be revisited under the light of the pharma-
cokinetic data available and concerns over patient
comfort in spite of the fact that the subcutaneous route
offers an opportunity of closer contact with a registered
nurse when pain control is a priority.
Higher utilization of methadone as a second-choice opi-
oid was observed in situations which usually require con-
sultation with the palliative care team, such as patients
with neuropathic pain and cases in which opioid rotation
was indicated [27]. Although methadone registered the
highest percentage increase, the total amount of metha-
done accounted for less than 10% of total opioids pre-
scribed. In a recent study which evaluated the prescription
of long acting opioids between 1996 and 2004 in an
Oncology Centre it was observed that the introduction of
a Palliative Care Service coincided with a reduction in the
use of fentanyl and an increase in the use of methadone
[28]. The data referring to oxycodone are too premature
and does not allow us to draw any conclusions; although
an increase in its consumption in coming years is expected
due to its role in opioid rotation in patients receiving mor-
phine [29].
In general, it may be assumed that the profile of opioid
use from 2004 onwards in this University Hospital reflects
an improvement in the knowledge and skills on the use of
opioids to meet the needs of cancer patients, since this is
where the faster action drug and presentations are
required. This change may be due not only to the direct
effect of the palliative care consultation team (which cares
for only 20% of the patients), but also to the influence it
may have had in the Oncology Department, resulting in
the prescription of the most appropriate drug profile to
suit the needs of the patients.
The data from this study suggests that the implementation
of PCCT in University Hospitals helps optimise the use of
opioids in patients with cancer pain. Further prospective
and comparative surveys on opioids prescription need to
be developed in hospital settings with and without pallia-
tive care consultation teams in order to establish indica-
tors and outcomes of efficiency of these specialized
resources.
This study is aim only to evaluate the effect of a PCCT on
opioid prescription. However, a PCCT should influence
advanced cancer management in other profiles. Although
pain is one and of the more common and relevant symp-
toms in Palliative Care, the origin of patient's sufferance
transcends pain and the influence of other physical,
social, psycho-emotional and spiritual factors that
requires adequate management can be elicited. The real
effect of a PCCT should be addressed including also its
impact in these other areas.
Conclusion
According to our data, the implementation of a PCCT in a
University Hospital is associated with an increase in total
opioid prescription in cancer patients. This increase is
bound to a change in the pattern of prescription, resulting
in a higher use of parenteral morphine and methadone
and a decrease in transdermal fentanyl. As a whole, these
changes can be interpreted as evidence not only of a
higher but a more adequate use of opioids that allows a
quicker adjustment and a better prevention and manage-
ment of opioid toxicity.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CC participated in the design and coordination of the
study, and in the data analysis and interpretation. MAP
participated in the collection and assembly of data and in
the data analysis and interpretation. AN participated in
the collection and assembly of data. AI participated in the
collection and assembly of data, and interpretation. ASR:
Participated in the design of the study, and in the data
analysis and interpretation. All authors read and approved
the final manuscript.
References
1. World Health Organization: Cancer pain relief and palliative
care.  WHO Technical Report Series 1990, 804:.
2. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart
JA, Pandya KJ: Pain and its treatment in outpatients with
metastasic cancer.  N Engl J Med 1994, 330:592-6.
3. Paregeom KL, Hailey BJ: Barriers to effective cancer pain man-
agement: a review of the literature.  J Pain Symptom Manage
1999, 109:281-3.
4. Carvajal A, García del Pozo J, Martín Arias LH, Martín de Diego I,
Rueda AM, Caro-Patón T, Alvarez Requejo A: Changes in the pat-
tern of opioid analgesic consumption in Spain.  Med Clin (Barc)
1997, 109:281-3.
5. Higginson IJ, Hearn J: A multicenter evaluation of cancer pain
control by palliative care teams.  J Pain Sympton Manage 1997,
14:29-35.
6. Strohscheer I, Verebes J, Samonigg H: Implementation of a Palli-
ative Care Team in an Austrian University Hospital.  Support
Care Cancer 2006, 14:795-801.
7. Virik K, Glare P: Profile and evaluation of a palliative medicine
consultation service within a tertiary teaching hospital in
Sydney.  J Pain Symptom Manage 2002, 23:17-25.
8. Weissmann DE: Consultations in palliative medicine.  Arch Intern
Med 1997, 157:733-7.
9. Cintron A, Meier D: The palliative care consult team.  In Text-
book of Palliative Medicine Edited by: Bruera E, Higginson I, Ripamonti
C, von Gutten C. London: Hodder Arnold; 2006:259-65. 
10. Palliative Care in Community Hospitals in Scotland a
Framework for Good Practice 2003. Scottish Association of
Community Hospitals and Scottish Partnership for Palliative
Care   [http://www.palliativecarescotland.org.uk/publications/]
11. Fischberg D, Meier DE: Palliative care in hospitals.  Clin Geriatr
Med 2004, 20:735-51.
12. Elsayem A, Swint K, Fisch MJ, Palmer JL, Reddy S, Walker P, Zhuko-
vsky D, Knight P, Bruera E: Palliative care inpatient service in aPage 6 of 7
(page number not for citation purposes)
BMC Palliative Care 2009, 8:2 http://www.biomedcentral.com/1472-684X/8/2Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Comprehensive Cancer Center: clinical and financial out-
comes.  J Clin Oncol 2004, 22:2008-14.
13. Bascom PB: A hospital-based comfort care team: consultation
for seriously ill and dying patients.  Am J Hosp Palliat Care 1997,
14:57-60.
14. Pan CX, Morrison RS, Meier DE: How prevalent are hospital-
based palliative care programs? Status report and future
directions.  J Palliat Med 2001, 4:315-24.
15. Centeno C, Clark D, Lynch T, Racafort J, Praill D, De Lima L, Green-
wood A, Flores LA, Brasch S, Giordano A, EAPC Task Force: Facts
and indicators on palliative care development in 52 countries
of the WHO European region: results of an EAPC task force.
Palliat Med 2007, 21:463-71.
16. Edmonds PM, Stuttaford JM, Penny J: Do Hospital Palliative Care
improve symptom control? Use of modified STAS as an eval-
uative tool.  Palliat Med 1998, 12:345-51.
17. Ellershaw JE, Peat SJ, Boys LC: Assessing the effectiveness of a
hospital palliative care team.  Palliat Med 1995, 9:145-52.
18. Bruera E, Brenneis C, Michaud M, McDonald R: Influence of the
pain and symptom control team (PSCT) on the patterns of
treatment of pain and other symptoms in a Cancer Center.
J Pain Symptom Manage 1989, 4:112-6.
19. World Health Organization: Cancer Pain Relief: With a Guide to
Opioid Availability.  Geneva. WHO; 1996. 
20. ACT/DDD Index 2007   [http://www.whocc.no/atcddd/indexdata
base/]
21. Portenoy RK, Lesage P: Management of cancer pain.  Lancet 1999,
353:1695-1700.
22. Eisenberg E, Adler R: Consumption of opioids in a hospital set-
ting. What can we learn from a 10 year follow-up?  IMAJ 2004,
6:.
23. Beuken-van Everdingen MHJ van den, de Rijke JM, Kessels AG,
Schouten HC, van Kleef M, Patijn J: Prevalence of pain in patients
with cancer: a systematic review of the past 40 years.  Ann
Oncol 2007, 18:1437-49.
24. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA: Validation of
World Health Organization Guidelines for cancer pain relief:
a 10-year prospective study.  Pain 1995, 63:65-76.
25. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S:
Symptoms during cancer pain treatment following WHO-
guidelines: a longitudinal follow-up study of symptom preva-
lence, severity and etiology.  Pain 2001, 93:247-57.
26. Bergman U: The history of the Drug Utilization Research
Group in Europe.  Pharmacoepidemiol Drug Safety 2006, 15:95-8.
27. Terpening CM, Johnson WM: Methadone as an analgesic: a
review of the risk and benefits.  W V Med J 2007, 103:14-8.
28. Curry EA, Palla S, Hung F, Arbuckle R, Bruera E: Prescribing pat-
terns and purchasing costs of long-acting opioids over nine
years at an academic oncology hospital.  Am J Health-Syst Pharm
2007, 64:1619-25.
29. Riley J, Ross JR, Rutter D, Wells AU, Goller K, du Bois R: No pain
relief from morphine? Individual variation in sensitivity to
morphine and the need to switch to an alternative opioid in
cancer patients.  Support Care Cancer 2006, 14:56-64.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-684X/8/2/prepubPage 7 of 7
(page number not for citation purposes)
